section name header

Indications ⬇

BEERS REMS


Equetro only

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: edema, heart block, HF, hypertension, hypotension, syncope

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), nail shedding, photosensitivity, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN), urticaria

EENT: blurred vision, corneal opacities, nystagmus

Endo: SIADH

F and E: hyponatremia

GI: ↑liver enzymes, HEPATOTOXICITY, PANCREATITIS

GU: urinary hesitancy, urinary retention

Hemat: AGRANULOCYTOSIS, APLASTIC ANEMIA, eosinophilia, leukopenia, lymphadenopathy, THROMBOCYTOPENIA

Metab: weight gain

Neuro: ataxia, drowsiness, fatigue, psychosis, sedation, SUICIDAL THOUGHTS, vertigo

Resp: pneumonitis

Misc: chills, fever

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Drug-Food:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Seizures

Trigeminal Neuralgia

Acute Manic or Mixed Episodes Associated With Bipolar I Disorder

US Brand Names ⬆ ⬇

Carbatrol, Equetro, TEGretol, TEGretol XR

Action ⬆ ⬇

  • Decreases synaptic transmission in the CNS by affecting sodium channels in neurons.
Therapeutic effects:
  • Prevention of seizures.
  • Relief of pain in trigeminal neuralgia.
  • Decreased mania.

Classifications ⬆ ⬇

Therapeutic Classification: anticonvulsants, mood stabilizers

Pharmacokinetics ⬆ ⬇

Absorption: Absorption is slow but complete. Suspension produces earlier, higher peak, and lower trough levels.

Distribution: Widely distributed to tissues. Crosses the blood-brain barrier.

Protein Binding: 75–90%.

Metabolism/Excretion: Extensively metabolized in the liver by the CYP3A4 isoenzyme to active epoxide metabolite; epoxide metabolite has anticonvulsant and antineuralgic activity.

Half-Life: Children: 8–14 hr; Adults: 12–17 hr.

Canadian Brand Names ⬆ ⬇

TEGretol CR

Time/Action Profile ⬆ ⬇

(anticonvulsant activity)

ROUTEONSETPEAKDURATION
POup to 1 mo‡4–5 hr‡6–12 hr
PO-ERup to 1 mo‡2–12 hr‡12 hr

‡Onset of antineuralgic activity is 8–72 hr.

‡Listed for tablets; peak level occurs 1.5 hr after a chronic dose of suspension.



Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆

kar-ba-MAZ-e-peen